Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, January 26, 2023
[ Thu, Jan 26th 2023
] - WOPRAI
[ Thu, Jan 26th 2023
] - WOPRAI
[ Thu, Jan 26th 2023
] - WOPRAI
[ Thu, Jan 26th 2023
] - WOPRAI
[ Thu, Jan 26th 2023
] - WOPRAI
[ Thu, Jan 26th 2023
] - WOPRAI
[ Thu, Jan 26th 2023
] - WOPRAI
[ Thu, Jan 26th 2023
] - WOPRAI
[ Thu, Jan 26th 2023
] - WOPRAI
[ Thu, Jan 26th 2023
] - WOPRAI
[ Thu, Jan 26th 2023
] - WOPRAI
[ Thu, Jan 26th 2023
] - WOPRAI
[ Thu, Jan 26th 2023
] - WOPRAI
[ Thu, Jan 26th 2023
] - WOPRAI
[ Thu, Jan 26th 2023
] - WOPRAI
[ Thu, Jan 26th 2023
] - WOPRAI
[ Thu, Jan 26th 2023
] - WOPRAI
[ Thu, Jan 26th 2023
] - WOPRAI
[ Thu, Jan 26th 2023
] - WOPRAI
[ Thu, Jan 26th 2023
] - WOPRAI
[ Thu, Jan 26th 2023
] - WOPRAI
[ Thu, Jan 26th 2023
] - WOPRAI
[ Thu, Jan 26th 2023
] - WOPRAI
[ Thu, Jan 26th 2023
] - WOPRAI
[ Thu, Jan 26th 2023
] - WOPRAI
[ Thu, Jan 26th 2023
] - WOPRAI
[ Thu, Jan 26th 2023
] - WOPRAI
[ Thu, Jan 26th 2023
] - WOPRAI
Mike Polark Initiated (TNDM) at Hold on, Jan 26th, 2023
Mike Polark of Wolfe Research, Initiated "Tandem Diabetes Care, Inc." (TNDM) at Hold on, Jan 26th, 2023.
Mike has made no other calls on TNDM in the last 4 months.
There are 5 other peers that have a rating on TNDM. Out of the 5 peers that are also analyzing TNDM, 1 agrees with Mike's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Larry Biegelsen of "Wells Fargo" Upgraded from Sell to Hold and Held Target at $43 on, Tuesday, November 15th, 2022
These are the ratings of the 4 analyists that currently disagree with Mike
- Jayson Bedford of "Raymond James" Maintained at Buy with Decreased Target to $52 on, Friday, November 4th, 2022
- Matt O'Brien of "Piper Sandler" Maintained at Buy with Decreased Target to $70 on, Thursday, November 3rd, 2022
- Matt Miksic of "Barclays" Initiated at Buy and Held Target at $75 on, Tuesday, October 18th, 2022
- Matthew Taylor of "Jefferies" Initiated at Strong Buy and Held Target at $75 on, Wednesday, October 12th, 2022
